A5043991810- Neuroendocrine Tumor Research Advances
- Lung Cancer Research Studies
- Neuroblastoma Research and Treatments
- Radiopharmaceutical Chemistry and Applications
- Prostate Cancer Treatment and Research
- Medical Imaging Techniques and Applications
- Pancreatic and Hepatic Oncology Research
- Advanced Radiotherapy Techniques
- Prostate Cancer Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- Pituitary Gland Disorders and Treatments
- Medical Imaging and Pathology Studies
- Cancer, Lipids, and Metabolism
- Cancer Immunotherapy and Biomarkers
- Cancer, Hypoxia, and Metabolism
- Cancer Diagnosis and Treatment
- Bone health and treatments
- Lung Cancer Treatments and Mutations
- Adrenal and Paraganglionic Tumors
- Soft tissue tumor case studies
- Advanced Biosensing Techniques and Applications
- Pelvic and Acetabular Injuries
- Diabetes and associated disorders
- Economic and Financial Impacts of Cancer
- Meningioma and schwannoma management
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori
2014-2023
Istituti di Ricovero e Cura a Carattere Scientifico
2014-2023
Policlinico S.Orsola-Malpighi
2008
<b><i>Background:</i></b> We evaluated the activity and safety profile of <sup>177</sup>Lu-DOTATATE peptide receptor radionuclide therapy (Lu-PRRT) in patients with advanced G1-G2 pancreatic neuroendocrine tumors. <b><i>Patients Methods:</i></b> Fifty-two consecutive were treated at two different therapeutic dosages 18.5 or 27.8 GBq five cycles, according to patient's kidney function bone marrow reserve, which are known be critical...
The complexity of the clinical management neuroendocrine neoplasia (NEN) is exacerbated by limitations in imaging modalities and a paucity clinically useful biomarkers. Limitations currently available reflect difficulties measuring an intrinsically indolent disease, resolution inadequacies inter-/intra-facility device variability that RECIST (Response Evaluation Criteria Solid Tumors) criteria are not optimal for NEN. used biomarkers they secretory (chromogranin A, serotonin, neuron-specific...
<h3>Importance</h3> Data about the optimal timing for initiation of peptide receptor radionuclide therapy (PRRT) advanced, well-differentiated enteropancreatic neuroendocrine tumors are lacking. <h3>Objective</h3> To evaluate association upfront PRRT vs chemotherapy or targeted with progression-free survival (PFS) among patients advanced who experienced disease progression after treatment somatostatin analogues (SSAs). <h3>Design, Setting, and Participants</h3> This retrospective,...
Pheochromocytoma and paraganglioma (PPGL) have currently only limited treatment options available for patients in the metastatic phase (mPPGL) either post-surgery or inoperable settings. However, these rare tumors overexpress somatostatin receptors can thus be treated with peptide receptor radionuclide therapy (PRRT). We present data about our 10-year experience treating 46 consecutive mPPGL 90Y-DOTATOC 177Lu-DOTATATE.All (20 men 26 women, median age 52 years) showed positive scintigraphic...
Paragangliomas (PGLs) are neuroendocrine tum-ors that arise embryologically from the neural crest. Sympathetic PGLs can be located in thoracic-abdominal region while parasympathetic mainly situated head and neck region. Most sporadic, but 30% of cases they hereditary (associated with mutations SDHB, SDHC, SDHD, SDHAF2, SDHA, TMEM, MAX, VHL); classified into 4 different paraganglioma syndromes: PGL1, PGL2, PGL3, PGL4. Surgery is treatment choice for both sympathetic PGLs. Other types include...
Radio-ligand therapy (RLT) with177Lu-PSMA-617 is a promising option for patients with metastatic castration-resistant prostate-cancer (mCRPC). A prospective phase-II study (EUDRACT/RSO,2016-002732-32) on mCRPC ongoing at IRST (Meldola, Italy). total of 9 (median age: 68 y, range: 53⁻85) were enrolled dosimetry evaluation parotid glands (PGs), kidneys, red marrow (RM) and whole body (WB). Folic polyglutamate tablets orally administered as PGs protectors 500 mL 10% mannitol solution was...
Six radium-223 injections at 4-week intervals is indicated for patients with castration-resistant prostate cancer and symptomatic bone metastases. However, usually develop disease progression after initial treatment. This prospective phase I/II study assessed re-treatment safety efficacy of up to six additional injections.Patients had metastases no on-treatment progression; all subsequent radiologic or clinical progression. Concomitant agents were allowed investigator discretion, excluding...